NEOPLASMS BY HISTOLOGIC TYPE

This early-stage study tests the safety of a new drug called ziftomenib when combined with standard chemotherapy for people whose acute myeloid leukemia (AML) has returned or not responded to treatment. The study includes adults with specific genetic changes (NPM1 mutation or KMT…

This study tests capmatinib, a drug already approved for certain lung cancers, in adults with other rare cancers that have specific MET gene changes. About 30 participants will receive the drug to see if their tumors shrink or stop growing for at least 24 weeks. The goal is to fi…

This study tests a drug called entrectinib, already approved for certain lung and solid tumors, in people with rare cancers that have a specific genetic change called ROS1 fusion. About 30 adults, teens, and children with these rare cancers will receive the drug. Researchers will…

This study tests alectinib, a drug already approved for some lung cancers, in patients with rare cancers that have an ALK gene change. About 30 adults and children with ALK-positive cancers will receive alectinib to see if it shrinks tumors or stops them from growing. The goal is…

This early-stage study tests a new gene therapy called KLN-1010 for people with multiple myeloma that has returned or not responded to treatment. Instead of removing cells, modifying them in a lab, and putting them back, this therapy aims to create cancer-fighting CAR-T cells dir…

This trial tests a drug called atezolizumab, already approved for some cancers, in people with rare cancers that have high numbers of genetic mutations or specific DNA repair problems. About 30 adults and children with these rare tumor types will receive the drug. The main goal i…

This early-stage trial tests a specially engineered virus, G207, in children and young adults whose cerebellar brain tumors have come back or not responded to standard treatments. The virus is injected directly into the tumor, and a single low dose of radiation is given to help t…